Circadian physiology is a toxicity target of the anticancer drug gemcitabine in mice

Journal of Biological Rhythms

Volumn 22, Issue 2, 2007, Pages 159-166

  Li, X M ^a   Levi F ^a  

^a INSERM   (France)

Author keywords

Body temperature; Cancer chemotherapy; Circadian rhythms; Gemcitabine; Locomotor activity; Mice; Telemetry transmitters

Indexed keywords

BIOLOGICAL MARKER; GEMCITABINE;

AMPLITUDE MODULATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY TEMPERATURE; CIRCADIAN RHYTHM; CONTROLLED STUDY; CONVALESCENCE; DOSE RESPONSE; DRUG EFFECT; FISHER EXACT TEST; IMPLANTATION; LIGHT DARK CYCLE; MALE; MOUSE; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; REST; RHYTHM; SINGLE DRUG DOSE; TELEMETRY; THERMOREGULATION; TOXICOKINETICS;

MUS;

EID: 34147104365     PISSN: 07487304     EISSN: 15524531     Source Type: Journal    
DOI: 10.1177/0748730406298984     Document Type: Article

References (35)

1. Abratt RP, Bezwoda WR, Falkson G., Goedhals L., Hacking D., and Rugg TA (1994) Efficacy and safety profile of gemcitabine in non-small cell lung cancer: A phase II study. J Clin Oncol 12: 1535-1540.
2. Bjarnason GA, Jordan Rck, and Sothern RB (1999) Circadian variation in the expression of cell-cycle proteins in human oral epithelium. Am J Pathol 154: 613-622.
3. Carmichael J., Fink U., Russell Rcg, Spittle MF, Harris AL, Spiessi G., and Blatter J. (1996) Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 73: 101-105.
4. Carmichael J., Possinger K., Phillip P., Beykirch M., Kerr H., Walling J., and Harris AL (1995) Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 13: 2731-2736.
5. Ceribelli A., Gridelli C., De Marinis F, Fabi A., Gamucci T., Cortesi E., Barduagni M., Antimi M., Maione P., Migliorino MR, et al. (2003) Prolonged gemcitabine infusion in advanced non-small cell lung carcinoma: a randomized phase II study of two different schedules in combination with cisplatin. Cancer 98: 337-343.
6. Cheng MY, Bullock CM, Li C., Lee AG, Bermak JC, Belluzzi J., Weaver DR, Leslie FM, and Zhou QY (2002) Prokineticin 2 transmits the behavioural circadian rhythm of the suprachiasmatic nucleus. Nature 417: 405-410.
7. De Pas T., Curigliano G., Franceschelli L., Catania C., Spaggiari L., and de Braud F. (2001) Gemcitabine-induced systemic capillary leak syndrome. Ann Oncol 12: 1651-1652.
8. Duncan WC (1996) Circadian rhythms and the pharmacology of affective illness. Pharmacol Ther 71: 253-312.
9. Gachon F., Olela FF, Schaad O., Descombes P., and Schibler U. (2006) The circadian PAR-domain basic leucine zipper transcription factors DBP, TEF, and HLF modulate basal and inducible xenobiotic detoxification. Cell Metab 4: 25-36.
10. Giacchetti S., Bjarnason G., Garufi C., Genet D., Iacobelli S., Tampellini M., Smaaland R., Focan C., Coudert B., Humblet Y., et al. (2006) Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: The European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol 24: 3562-3569.
11. Granda TG, Liu XH, Smaaland R., Cermakian N., Filipski E., Sassone-Corsi P., and Lévi F. (2005) Circadian regulation of cell cycle and apoptosis proteins in mouse bone marrow and tumor. FASEB J 19: 304-306.
12. Hrushesky W. (1985) Circadian timing of cancer chemotherapy. Science 228: 73-75.
13. Kaye SB (1994) Gemcitabine: Current status of phase I and II trials. J Clin Oncol 12: 1527-1531.
14. Kramer A., Yang FC, Snodgrass P., Li X., Scammell TE, Davis FC, and Weitz CJ (2001) Regulation of daily locomotor activity and sleep by hypothalamic EGF receptor signaling. Science 294: 2511-2515.
15. Kraves S. and Weitz CJ (2006) A role for cardiotrophin-like cytokine in the circadian control of mammalian locomotor activity. Nat Neurosci 9: 212-219.
16. Lévi F., Cornelissen G., Nelson W., and Halberg F. (1981) Cisplatine murine chrononephrotoxicity gauged by two marker rhythms: Urine volume and telemetered intraperitoneal temperature. In Chronopharmacology, Walter CA, Soliman KFA, and Winger W, eds, pp 363-377, University Presses of Florida, Tallahassee.
17. Lévi F., Focan C., Karaboué A., de la Valette V., Focan-Henrard D., Baron B., Kreutz M., and Giacchetti S. (In press) Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Adv Drug Deliv Rev.
18. Lévi F. and Schibler U. (2007) Circadian rhythms: Mechanisms and therapeutic implications. Annu Rev Pharmacol Toxicol 47: 593-628.
19. Lévi F., Zidani R., and Misset JL (1997) Randomized multi-centre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 350: 681-686.
20. Li XM, Tanaka K., Sun J., Filipski E., Kayitalire L., Focan C., and Lévi F. (2005) Preclinical relevance of dosing time for the therapeutic index of gemcitabine-cisplatin. Br J Cancer 92: 1684-1689.
21. Li XM, Vincenti M., and Lévi F. (2002) Pharmacological effects of vinorelbine on body temperature and locomotor activity circadian rhythms in mice. Chronobiol Int 19: 43-55.
22. Lopez-Olmeda JF, Bayarri MJ, Rol de Lama MA, Madrid JA, and Sanchez-Vazquez FJ (2006) Effects of melatonin administration on oxidative stress and daily locomotor activity patterns in goldfish. J Physiol Biochem 62: 17-25.
23. Lund B., Hansen OP, Theilade K., Hansen M., and Neijt JP (1994) Phase II study of gemcitabine (2', 2' -difluorodeoxycytidine) in previously treated ovarian cancer. J Natl Cancer Inst 86: 1530-1533.
24. Maraveyas A., Sgouros J., Upadhyay S., Abdel-Hamid AH, Holmes M., and Lind M. (2005) Gemcitabine twice weekly as a radiosensitiser for the treatment of brain metastases in patients with carcinoma: a phase I study. Br J Cancer 92: 815-819.
25. Mormont MC, Waterhouse J., Bleuzen P., Giacchetti S., Jami A., Bogdan A., Lellouch J., Misset JL, Touitou Y., and Lévi F. (2000) Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res 6: 3038-3045.
26. Morrow GR, Andrews Plr, Hickok JT, Roscoe JA, and Matteson S. (2002) Fatigue associated with cancer and its treatment. Support Care Cancer 10: 389-398.
27. Nelson A., Tong Y., Lee JK, and Halberg F. (1979) Methods for cosinor rhythmometry. Chronobiologia 6: 305-323.
28. Ohdo S., Koyanagi S., Suyama H., Higuchi S., and Aramaki H. (2001) Changing the dosing schedule minimizes the disruptive effects of interferon on clock function. Nat Med 7: 356-360.
29. Rich T., Innominato PF, Boerner J., Mormont MC, Iacobelli S., Baron B., Jasmin C., and Levi F. (2005) Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin Cancer Res 11: 1757-1764.
30. Ron IG, Peleg L., Rienstein S., Dotan A., Ticher A., Wolfson S., and Ashkenazi IE (1998) Dependency of hematopoietic growth factor coupled to chronotoxicity of carboplatin. Cancer Chemother Pharmacol 42: 135-141.
31. Rosado MF, Kett DH, Schein RM, Baraona FJ, and Sridhar KS (2002) Severe pulmonary toxicity in a patient treated with gemcitabine. Am J Clin Oncol 25: 31-33.
32. Ruiz van Haperen Vwt, Veerman G., Vermorken JB, and Peters GJ (1993) 2', 2' -Difluorodeoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cells. Biochem Pharmacol 46: 762-766.
33. Scremin OU, Shih TM, Huynh L., Roch M., Sun W., Chialvo DR, and Jenden DJ (2006) Circadian rhythms of heart rate and locomotion after treatment with low-dose acetylcholinesterase inhibitors. J Appl Toxicol 26: 410-418.
34. Wagner LI and Cella D. (2004) Fatigue and cancer: Causes, prevalence and treatment approaches. Br J Cancer 91: 822-828.
35. Xu YZ and Plunkett W. (1992) Modulation of deoxycytidylate deaminase in intact human leukemia cells-Action of 2', 2'-difluorodeoxycytidine. Biochem Pharmacol 45: 1819-1827.